Last reviewed · How we verify
Long DOAC
At a glance
| Generic name | Long DOAC |
|---|---|
| Sponsor | Takeshi Morimoto |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry
- DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
- Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer (PHASE4)
- LAA Clipping Versus NOACs to Prevent Stroke in Non-paroxysmal Atrial Fibrillation. (NA)
- Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation (NA)
- EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Long DOAC CI brief — competitive landscape report
- Long DOAC updates RSS · CI watch RSS
- Takeshi Morimoto portfolio CI